MAHA Commission Report on Children’s Health Takes Aim at Ultra-Processed Foods and Medication Practices, Among Other Targets

May 23, 2025

Reading Time : 2 min

Yesterday, the White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. released its inaugural health report titled, Make Our Children Healthy Again, delivering one of the first widely anticipated deliverables from the MAHA Commission Executive Order issued earlier this year and noted in our prior alert. The 72-page assessment examines the rising rates of childhood chronic disease in the country—including obesity, heart disease and diabetes—and explores potential contributing factors. Specifically, the report identifies and focuses on four potential drivers:

  • Ultra-Processed Foods (UPFs). The report links the increased consumption of UPFs high in added sugars, chemical additives and saturated fats to poor health outcomes in children. The report also states that government programs such as the Supplemental Nutrition Assistance Program (SNAP) and the School Breakfast Program and National School Lunch Program (NSLP) have contributed to the overconsumption of UPFs.
  • Exposure to Environmental Chemicals. The Commission identifies a need for continued studies to better understand the impact of exposure to various substances including per- and polyfluoroalkyl substances (PFAS), fluoride, electromagnetic radiation and phthalates.
  • Lack of Physical Activity and Chronic Stress: The report discusses the pervasive use of screens, increasing sedentary lifestyles and childhood mental health decline as areas of concern.
  • Overmedicalization: The report states that “excessive medical intervention” including an overuse of prescription drugs and vaccines may exacerbate chronic childhood illness. The report calls for inquiry into the impacts of vaccine injury, links between vaccines and chronic disease, and conflicts of interest in the development of the vaccine schedule.

Next Steps

The report outlines ten proposed research initiatives, setting the stage for follow-on actions and potential policy changes as the MAHA Commission’s work moves forward. The report identifies ten areas for further research, including recommending several research initiatives to guide efforts to combat childhood chronic disease including evaluating self-affirmed GRAS (Generally Recognized as Safe) food ingredients, assessing the impact of whole-food, reduced-carb and low-UPF diets in children, and applying AI and machine learning to federal health and nutrition datasets for early detection of harmful exposures and childhood chronic disease trends. The report also proposes focusing on research replication, post-marketing surveillance, leveraging real world data to study childhood chronic diseases, drug safety studies, alternative testing models, and mapping gene–environment interactions affecting childhood disease risk. The MAHA Commission plans to release a strategy in August 2025. However, it is likely that the Commission will provide updates on some of these research items before August, and agencies such as FDA and NIH will likely start announcing initiatives based on this report.

Share This Insight

Previous Entries

Eye on FDA

July 22, 2025

Dr. George Tidmarsh has been selected to replace Dr. Jacqueline Corrigan-Curay as the director of the Center for Drug Evaluation and Research (CDER) at FDA as she prepares to retire from the agency. Dr. Tidmarsh is an adjunct professor of pediatrics and neonatology at Stanford University and is credited as having been involved in the development of several approved drugs. Until late May of this year, Dr. Tidmarsh was a member of the board of directors of Revelation Biosciences, a company engaged in developing an anti-inflammatory IV therapy. Among other roles and experiences he has had, he was a founding Co-Director of Stanford’s Master of Science in Translational Research and Applied Medicine (M-TRAM) program, and founded Horizon Pharma in 2005.

...

Read More

Eye on FDA

July 16, 2025

Recently, it was reported that the U.S. Food and Drug Administration (FDA) is launching two cross-agency artificial intelligence (AI) councils. One AI council will be tasked with addressing how the agency uses AI internally and the other will focus on policy governing AI’s use in FDA-regulated products (reportedly pre-existing AI councils in various FDA divisions will continue to operate) (Politico Pro).

...

Read More

Eye on FDA

July 16, 2025

This week, the U.S. Food and Drug Administration (FDA) granted another color additive petition, approving the use of Gardenia (Genipin) in various food and beverage products. This marks the fourth naturally-derived color additive authorized for use in foods since FDA’s April announcement to phase out all petroleum-based synthetic dyes in food and transition to natural alternatives (read more here). Gardenia blue, derived from the fruit of the gardenia, a flowering evergreen, is now approved for use in sport drinks, flavored or enhanced non-carbonated water, fruit drinks and ades, ready-to-drink teas, hard candy and soft candy.

...

Read More

Eye on FDA

July 10, 2025

This morning, the U.S. Food and Drug Administration (FDA) announced the publication of more than 200 decision letters, also known as complete response letters (CRLs), with plans to release more from the archives. The CRLs released today are associated with applications for drugs and biologics submitted for approval between 2020 and 2024 that have since been approved by the agency.

...

Read More

Eye on FDA

June 26, 2025

On June 24, 2025, in a hearing before the U.S. House of Representatives Committee on Energy and Commerce, the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. revealed that his department plans to soon launch an advertising campaign encouraging Americans to use wearable health devices. The campaign is set to be “one of the biggest advertising campaigns in HHS history.”

...

Read More

Eye on FDA

June 20, 2025

On June 17, 2025, the U.S. Food and Drug Administration (FDA) announced the Commissioner’s National Priority Voucher (CNPV) program, a new program that aims to speed up drug application review for companies aligned with U.S. national priorities. In terms of qualifying for the program, the key differentiator between this program and other “priority” review programs is that the application must support increased domestic drug manufacturing—presumably meaning that the applicant commits to manufacture the drug in the United States. The key benefit is that drug developers can redeem the vouchers to accelerate their application review time from 10-12 months to one to two months after a sponsor’s final drug application submission. The program includes enhanced communication with the sponsor and will utilize a team-based review process, in which a multidisciplinary team of FDA experts, who will prereview clinical information, gather for a one-day “tumor board style” meeting. While some of the review work is envisioned to be “front loaded” before the actual application is submitted, it is still the case that a two-month review window would be a radical acceleration of the review timeline compared to standard review times.

...

Read More

Eye on FDA

June 16, 2025

Last week, the U.S. Food and Drug Administration (FDA) released two educational videos and a supplemental fact sheet to guide dietary supplement manufacturers and distributors through the New Dietary Ingredient Notification (NDIN) review process. Under Section 413 of the Federal Food, Drug, and Cosmetic Act, manufacturers and distributors must submit an NDIN to notify FDA before marketing a dietary supplement with a new dietary ingredient. These resources offer guidance on structuring submissions and outline what to expect during the agency’s review. Ultimately, they are intended to enhance the quality of NDIN submissions and minimize common pitfalls, with the goal of avoiding delays or unfavorable results in the agency’s review.

...

Read More

Eye on FDA

June 5, 2025

Over the weekend, the Department of Justice (DOJ) did not file an appeal of the U.S. District Court for the Eastern District of Texas’ decision to vacate and set aside the agency’s final rule on the regulation of laboratory developed tests (LDTs), titled Medical Devices; Laboratory Developed Tests (the LDT Rule). The LDT Rule would have required laboratories to ensure that their offered LDTs met medical device requirements under a multistage phase out of Food and Drug Administration’s (FDA) enforcement discretion policy. While the government’s decision not to appeal this ruling may not have been a surprise, questions remain as to how FDA plans to clarify its policy towards lab test offerings going forward.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.